Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

On November 17, 2025 Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics, Triclonics and ADClonics), and Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme"), a leader in subcutaneous drug delivery solutions, reported they have entered into a global non-exclusive collaboration and license agreement. Under the collaboration, Merus has licensed Halozyme’s ENHANZE drug delivery technology, for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Petosemtamab continues to show encouraging results in the clinical studies across numerous solid tumor cancers and has the potential to become a first and best in class treatment in head and neck cancer and beyond. We are proud to collaborate with Halozyme and look forward to working closely with their team on a subcutaneous administration," said Peter Silverman, Chief Operating Officer, General Counsel of Merus.

"We are excited to collaborate with Merus to advance treatment options for patients with r/m HNSCC and other potential indications," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "This collaboration represents a new opportunity for our ENHANZE technology to improve treatment efficiency and enhance the patient treatment experience. Together, we aim to accelerate innovation for patients and healthcare providers."

Under the terms of the agreement, Merus will make an upfront payment to Halozyme, and potential future milestone payments related to commercial and sales attainment, if approved. Halozyme will also be entitled to up to low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term.

(Press release, Merus, NOV 17, 2025, View Source [SID1234660030])